A systematic review and meta-analysis of inpatient mortality 1 associated with nosocomial and community COVID-19 exposes the 2 vulnerability of immunosuppressed adults 3 4 5 **Authors** Mark J. Ponsford, BMBCh MSc, Clinician Scientist 1,2\*,† 6 Tom JC Ward, MBBS, PhD, Clinical Lecturer in Respiratory Medicine <sup>3,4</sup> † 7 8 Simon Stoneham, BMBCh MRes, Specialist Registrar in Infectious Diseases and Microbiology <sup>5</sup> 9 Clare M. Dallimore, MBBS, Anaesthetic Specialist Registrar <sup>6</sup> 10 Davina Sham, MBBS, Paediatric Specialist Registrar <sup>7</sup> 11 Khalid Osman, MBBS, Foundation Trainee 8 12 Simon Barry, MB BS PhD, Consultant Respiratory Medicine 8,9 13 14 Stephen Jolles, MB BS MSc PhD, Professor and Consultant Immunologist <sup>1</sup> Ian R. Humphreys, PhD, Professor and Wellcome Trust Senior Research Fellow <sup>2,10</sup> 15 Daniel Farewell, PhD, Reader in Statistics 11 16 17 18 \* Corresponding author 19 † Joint equal first authors

- 20 Affiliations
- 21 Immunodeficiency Centre for Wales, University Hospital for Wales, Heath Park, Cardiff,
- 22 UK
- <sup>2</sup> Henry Wellcome Building, Division of Infection & Immunity, School of Medicine, Cardiff
- 24 University, UK.
- <sup>3</sup>College of Life Sciences, Department Respiratory Sciences, University of Leicester,
- 26 University Road, Leicester LE1 7RH
- <sup>4</sup> Institute for Lung Health, NIHR Leicester Biomedical Research Centre, Glenfield Hospital,
- 28 Leicester, UK
- <sup>5</sup> Department of Global Health and Infection, Brighton and Sussex Medical School,
- 30 University of Sussex, Brighton, UK.
- 31 <sup>6</sup> Department of Anaesthetics, University Hospital for Wales, Heath Park, Cardiff, UK
- 32 <sup>7</sup> University Hospitals of Leicester NHS Trust, Leicestershire, UK
- 33 <sup>8</sup> Department of Respiratory Medicine, Cardiff and Vale University Health Board, Cardiff,
- 34 UK
- 35 <sup>9</sup> Respiratory Health Implementation Group, Swansea University, Swansea, UK.
- 36 <sup>10</sup> Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff,
- 37 UK.
- 38 <sup>11</sup> Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK.
- 40 **Correspondence to:** Dr Mark J Ponsford; ponsfordm@cardiff.ac.uk
- 41 Keywords: covid-19, nosocomial, mortality, infection, immunodeficiency, risk. (Min.5-
- 42 **Max. 8**)

Abstract

- 45 **Background**: Little is known about the mortality of hospital-acquired (nosocomial) COVID-
- 46 19 infection globally. We investigated the risk of mortality and critical care admission in
- 47 hospitalised adults with nosocomial COVID-19, relative to adults requiring hospitalisation
- 48 due to community-acquired infection.
- 49 **Methods**: We systematically reviewed the peer-reviewed and pre-print literature from
- 50 1/1/2020 to 9/2/2021 without language restriction for studies reporting outcomes of
- 51 nosocomial and community-acquired COVID-19. We performed a random effects meta-
- 52 analysis (MA) to estimate the 1) relative risk of death and 2) critical care admission,
- 53 stratifying studies by patient cohort characteristics and nosocomial case definition.
- Results: 21 studies were included in the primary MA, describing 8,246 admissions across 8
- countries during the first wave, comprising 1517 probable or definite nosocomial COVID-19,
- and 6729 community-acquired cases. Across all studies, the risk of mortality was 1.31 times
- 57 greater in patients with nosocomial infection, compared to community-acquired (95% CI:
- 58 1.01 to 1.70). Rates of critical care admission were similar between groups (Relative Risk,
- 59 RR=0.74, 95% CI: 0.50 to 1.08). Immunosuppressed patients diagnosed with nosocomial
- 60 COVID-19 were twice as likely to die in hospital as those admitted with community-acquired
- 61 infection (RR=2.14, 95% CI: 1.76 to 2.61).
- 62 **Conclusions:** Adults who acquire SARS-CoV-2 whilst already hospitalised are at greater risk
- of mortality compared to patients admitted following community-acquired infection; this
- 64 finding is largely driven by a substantially increased risk of death in individuals with
- 65 malignancy or who had undergone transplantation. These findings inform public health and
- 66 infection control policy, and argue for individualised clinical interventions to combat the
- 67 threat of nosocomial COVID-19, particularly for immunosuppressed groups.
- 68 Systematic review registration: PROSPERO CRD42021249023

1 Introduction

69

70 Health-care-associated infections represent an enduring and serious threat to patient safety 71 (1,2), and are estimated to cost the National Health Service (NHS) £1 billion each year (3). 72 The transmission of respiratory viruses such as influenza in the healthcare environment are a 73 well-recognized cause of significant morbidity and mortality at the individual patient level 74 (4), however less is known regarding the significance of in-hospital (nosocomial) 75 transmission of the novel pandemic coronavirus SARS-CoV-2 causing COVID-19 (5). Since 76 its emergence in 2019, COVID-19 has placed enormous pressure on health-care systems 77 worldwide. Limited availability of testing, asymptomatic infections, and an evolving 78 understanding of routes of transmission have led to the exposure of potentially vulnerable 79 uninfected patients in the health-care setting (6). 80 The first and only rapid literature review and meta-analysis conducted to date on nosocomial 81 COVID-19 in hospitalised individuals was published in April 2020, early in the course of the 82 pandemic, and included only 3 studies reporting prevalence (7). The UK COVID-19 Clinical 83 Information Network (CO-CIN) estimated 31,070 nosocomial COVID-19 infections occurred 84 in England between February and July 2020, but made no assessment of the risk of mortality 85 (8). We recently reported our initial experience from the first wave of the COVID-19 86 pandemic across the nation of Wales, using data collected from 2508 hospitalised adults (9). 87 In this observational study, inpatient mortality rates for nosocomial COVID-19 ranged from 88 38% to 42% and were consistently higher than participants with community-acquired 89 infection (31% to 35%) across a range of possible case definitions. Whilst supported by other studies (10,11), this finding contrasts with several earlier reports suggesting that nosocomial 90 91 COVID-19 infection is associated with a similar risk of inpatient mortality to community 92 acquired infection (12–14). 93 It is well known that individuals with pre-existing health conditions particularly ischemic 94 heart disease, diabetes, hypertension and immunosuppression (15–17), as well as older and 95 frailer individuals (18), are at increased risk of death from SARS-CoV-2. Such individuals 96 are also likely to be over-represented in inpatient cohorts (19). Together, this suggests a 97 robust assessment of the burden of mortality is urgently needed to examine the risk to 98 patients, identify vulnerable cohorts, and direct policies to ensure improvement. We therefore 99 performed a systematic review and meta-analysis of published and pre-print studies reporting 100 mortality associated with probable and definite nosocomial SARS-CoV-2 outbreaks during

the first wave of the COVID-19 pandemic. Our primary aim was to compare case fatality rates of nosocomial and community-acquired COVID-19 cases within hospitalised adults. Our secondary aims were to assess the variation in risk of mortality between patient subgroups, the relative risk of critical care admissions, and to probe the risk of bias associated with these reports. Together, this provides a timely insight to the global burden of hospital-acquired COVID-19, and highlights key patient groups at elevated risk of mortality due to nosocomial exposure. These findings inform public health policy, and argue for enhanced infection control alongside and access to clinical interventions to combat the threat of nosocomial COVID-19.

#### 2 Methods

111

115

- We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- 113 (PRISMA) 2020 (20). The study protocol was prospectively registered with Prospero
- (CRD42021249023), having first confirmed no similar reviews were underway.

#### 2.1 Eligibility criteria

#### 116 **2.1.1 Participants**

- 117 Studies of hospitalised adults (≥16 years) within acute or long-term healthcare settings,
- excluding care or residential homes. We specifically focused on outcomes for hospitalised
- adults and excluded outcomes from health care workers with nosocomial infection, as the
- 120 latter has been recently evaluated (21).

### 121 **2.1.2 Exposures**

- We included any implicit or explicit case definition of probable or definite nosocomial
- acquisition as defined by the study authors, considering these further in sensitivity analyses.
- 124 Patients where COVID-19 origin was unclassified were excluded. Implementation of
- universal screening of patients and healthcare workers, and changes to personal protective
- equipment have recently been reported in detail elsewhere (22) and were not further
- 127 considered.

#### **2.1.3 Comparators**

- 129 The number and outcome of adults hospitalised with community-acquired SARS-CoV-2
- within the same study setting.

#### 131 **2.1.4 Outcomes**

- 132 The primary outcome was mortality of nosocomial SARS-CoV-2 infections in hospitalised
- adult patients and community-acquired SARS-CoV-2 infection. Secondary outcomes
- included rates of critical care admission, and qualitative analysis of case definitions, study
- timing, and variation in reporting by country of origin.

### 136 **2.1.5 Study design**

- Observational case series and cohort studies were included, provided they reported an
- outbreak of nosocomial SARS-CoV-2 (defined as ≥2 patients with likely nosocomial

- infection) within the hospital setting. Case reports with a single participant (high risk of bias,
- unable to assess proportion/risk), exclusively outpatient populations (e.g. dental practice), and
- non-patient populations (e.g. healthcare workers only) were therefore excluded.

## 142 **2.2** Search strategy to identify studies

#### 2.2.1 Database search strings

- Ovid Medline, Embase, and the Social Policy & Practice databases and MedRvix.org were
- searched from 1/1/2020 to 9/2/2021. A search string was designed that included the following
- 146 concepts: [SARS-CoV-2 OR sars-cov 2 OR COVID-19 OR covid 19 OR 2019-nCoV or
- "COVID-19"] AND [nosocomial OR hospital-acquire\* or nosocomial-acquire\* OR cross
- infection.

143

#### 149 **2.2.2 Restriction on publication type**

- No restrictions by language were imposed, and Google Translate was used to review full text
- documents where required. In addition to considering full-text articles, publications available
- as abstract only were included if they contained sufficient information to inform the primary
- 153 outcome.

164

#### 154 2.2.3 Study selection and screening

- Five clinicians (MJP, TJCW, SS, DS, KO, CD) independently screened titles and abstracts
- against inclusion criteria using Rayyan (23). MJP retrieved the full-texts, and with TJCW and
- 157 SS screened these for inclusion. Conflicts were resolved by consensus. The selection process
- is outlined in the PRISMA flow diagram (Figure 1).

#### 159 **2.3 Data extraction**

- Data was extracted using a pre-defined spreadsheet with fields as presented in Table 1, and
- 161 cross-checked for accuracy and completeness by a second reviewer. COVID-19 case
- diagnosis rates by country were retrieved from https://ourworldindata.org/coronavirus-
- source-data on 6th April 2021.

#### 2.4 Assessment of risk of bias

- Formal risk of bias on a study and outcome level were conducted using the Newcastle Ottawa
- Score (NOS) for cohort studies and Joanna Briggs Institute (JBI) tools for case series and

prevalence studies (24), as recommended by the National Institute for Clinical Excellence (NICE) (25). Assessment was performed by 2 independent reviewers, with arbitration with a third as required. We defined adequate follow-up as ≥28 days, or complete follow-up until death or discharge, to account for the potential unequal time points in disease course at study entry between community and nosocomial patients. We considered principal areas likely to introduce bias, indicated by \* in Tables 2-4, equating to a minimum score of 5 across tools. Briefly, these assessed quality of selection: a) representativeness of the average nosocomial covid-19 case within the patient group, based on study design, b) ascertainment bias − requiring evidence of methods to mitigate this, c) sufficient description of study subjects and case definition − requiring an explicit nosocomial case definition given and applied; and quality of outcome assessment: a) sufficient follow-up, and b) adequacy of follow-up requiring sufficient participants to have reached the pre-specified outcome at time of reporting.

#### 2.5 Data Analysis

167

168

169

170

171

172

173

174

175

176

177

178

179

- Analysis was performed using R version 4.0.2 in RStudio (Version 1.3.959, R Foundation,
- 182 Vienna, Austria) using the metafor package. Full details can be found within the online
- supplementary methods. Briefly, a random effects model was used to compare relative risk of
- mortality and ICU admission between patients with community-acquired and nosocomial
- 185 COVID-19. Full details of the statistical methods used are available at https://cran.r-
- project.org/web/packages/metafor/metafor.pdf. Residual maximum likelihood (REML) was
- used to estimate the heterogeneity variance  $(\tau^2)$  (26). We conducted subgroup analyses based
- on classifications agreed by the reviewers reflecting the cohort best represented by the
- studies, i.e. in cohorts that were clinically and methodologically similar (27). Cochrane's Q-
- test and  $I^2$  were used to assess the degree of inconsistency across studies (28,29). Two-sided
- 191 statistical significance was set at p<0.05. We conducted the following pre-specified
- sensitivity analyses:
- 1: Studies providing an explicit definition of nosocomial acquisition
- 2: Studies providing outcomes associated with a standardised >14 day definition for 'definite' nosocomial covid-19
- 3A: Excluding studies with a higher risk of bias (indicated by total quality score <5)
- 3B: Fulfilling all 5 core study quality domains (indicated by \* within tables 2-4).
- 4: Excluding studies with imputed data (i.e. 0.5 used in place of zero-count cells)

Additional data visualization was performed in R using the ggplot2 package.

#### 2.6 Reporting bias assessment

- Funnel plot and Egger's test were used to assess for potential publication bias, supported by
- 203 qualitative evaluation.

200

201

### 204 **2.7** Certainty assessment

- 205 The certainty of evidence was rated using the Grading of Recommendations, Assessment,
- Development and Evaluations (GRADE) approach (30) using the GRADEPro online tool,
- 207 <a href="https://gradepro.org/">https://gradepro.org/</a>.
- **208 3 Results**

#### 209 3.1 Study selection and characteristics

- 210 We screened a total of 1478 unique abstracts and reviewed 195 full texts to identify 67
- 211 studies describing hospital nosocomial COVID-19 outbreaks. Principal reasons for study
- 212 exclusion are shown in Figure 1. A further 48 studies were excluded as they did not report
- 213 mortality within both community and nosocomial-acquired COVID-19 patient groups. This
- 214 left 21 studies for primary meta-analysis (9–13,31–46), summarised in Table 1, with both
- 215 retrospective (n=14) and prospective (n=7) study designs including a range of medical and
- 216 surgical patient populations. Together, these described 8246 hospitalised adults admitted
- between 1<sup>st</sup> March 2020 and 13<sup>th</sup> July 2020 across 7 countries, comprising 1517 (18%)
- 218 probable or definite nosocomial COVID-19 and 6729 (82%) community-acquired cases.
- Overall mortality was 30.5% (2516/8246), with 575 deaths attributed to nosocomial COVID-
- 220 19 (37.9% mortality rate) and 1941 (28.9% mortality rate) to community-acquired COVID-
- 221 19. An additional study reporting the critical care admissions but without mortality by
- probable-nosocomial origin was identified, and is included Table 1 (47).

# Figure 1: PRISMA diagram

224

225

226

#### Table 1: Evidence summary for studies included within meta-analyses

#### 3.2 Study timing in pandemic course and availability of universal RT-PCR testing

We explored the timing of patient identification within these reports relative to national

COVID-19 diagnosis rates based on publicly available data within the UK (Figure 2), and

wider countries (Supplementary S2). All included studies dealt with the initial wave of the

pandemic. Consistent with the early timing of these reports, no studies reported the use of

universal RT-PCR screening of patients in prior to or during admission from the outset of the

study, outside of the setting nosocomial outbreaks.

#### Figure 2: Timing of UK studies relative to national COVID-19 diagnosis rates

#### 3.3 Case definitions

227

228229

230

231

232

233

234

235

236

237

239

240

241

242

243

244

245

246

247

248

249

250

251

238 A positive reverse transcription polymerase chain reaction (RT-PCR) SARS-CoV-2 result

was explicitly used as primary method of diagnosis in 17/21 studies included in the mortality

meta-analysis (76%), supported by clinical-radiological features (12,33,41), or based upon

laboratory-based diagnosis (potentially including serology) (43,45). As shown in Table 1, a

range of case definitions were employed to distinguish community-acquired and nosocomial

COVID-19. A fixed interval between admission and diagnosis was employed in 14/21 (62%)

ranging from >2 days (45) to >14 days (12), supplemented by additional patient-level clinical

data (41) and viral whole genome sequencing (32). Seven studies primarily employed

epidemiological nosocomial definitions, for instance a history of close contact with positive

cases (n=3, (31,39,43)), or the absence of symptoms on admission with subsequent positive

test (n=2, (10,35)). Two studies gave no explicit nosocomial case definition (33,36). Four

studies (19%) explicitly considered patients who had been recently discharged.

#### 3.4 Risk of bias in studies

- We screened study quality through self-identified use of reporting standards. Three (14%)
- 253 reports referenced the STrengthening the Reporting of OBservational studies in
- 254 Epidemiology (STROBE) statement (9,12,36). Tables 2-4 show the formal risk of bias
- assessments. Overall, 17/21 (81.0%) achieved a total score of 5 or more. Utilising our more

- 256 stringent assessment of study quality across all core domains (indicated by \*) only 9/21
- 257 (43.0%) were identified, with 80% case series, 62.5% cohort, and 37.5% of prevalence rated
- at high risk of bias.

- 259 Table 2: Risk of Bias Assessment cohort studies (n=8)
- 260 Table 3: Risk of bias assessment prevalence studies (n=8)
- Table 4: Risk of bias assessment case series (n=5)
- 263 3.5 Meta-analysis of mortality in patients with nosocomial relative to community-
- 264 **acquired COVID-19**
- Meta-analysis using a random effects model is shown in Figure 3. Across 21 studies, the risk
- of mortality was 1.31 (95% CI: 1.01 to 1.70) times greater in patients with probable or
- 267 definite nosocomial infection, compared to those admitted with community-acquired
- 268 COVID-19. Substantial heterogeneity was evident between the included studies (Q= 76.3, p <
- 0.0001;  $I^2 = 82.3\%$ , 95% CI: 62.0 to 94.6%). We performed sub-grouping by patient cohort
- 270 characteristics, including an immunosuppressed sub-group comprising 3 studies reporting
- outcomes from adult recipients of solid-organ or bone marrow transplants, or with a diagnosis
- of haematological or solid-organ cancers. These 1069 patients (152 nosocomial, 917
- community-acquired) showed an elevated risk of death associated with nosocomial COVID-
- 274 19, relative to those with community-acquired infection: RR= 2.14, 95% CI: 1.76 to 2.61.
- 275 This effect appeared consistent across the 3 studies, but with considerable uncertainty
- associated with estimates of heterogeneity (O=1.24, p=0.54;  $I^2=0.00\%$ , 95% CI: 0.00 to
- 277 96.6%). General medical and geriatric admissions were also suggesting of an increased risk
- of mortality with nosocomial COVID-19 (RR 1.14 and 1.35 respectively), but did not reach
- 279 statistical significance.

280

282

281 Figure 3: Relative risk of mortality

#### 3.6 Meta-analysis of critical care admission

- 284 Critical care admission rates were reported in 8 studies reporting nosocomial outbreaks
- 285 (11,13,34,39,42,44,45,47); with a crude rate of 27/252 (10.7%) in patients with nosocomial
- 286 COVID-19 compared to 359/1396 (25.7%) in those hospitalised with community-acquired
- 287 COVID-19. Meta-analysis is shown in Figure 4, with the pooled relative risk indicating this
- trend did not reach statistical significance (RR= 0.70, 95% CI: 0.48 to 1.03).

#### Figure 4: Relative risk of critical care admission

#### 3.7 Sensitivity analysis

283

289

290

291

292

305

- 293 To challenge the robustness of our findings, we examined the effect of varying the level of
- 294 certainty of nosocomial case diagnosis, study quality, and use of imputed mortality data
- across 5 sensitivity analyses, and assessed if individual studies conferred undue influence
- 296 (Supplementary S3). These suggested that no individual study had undue influence on the
- 297 results. Exclusion of studies across all sub-groups led to similar point estimates for the
- 298 relative risk of mortality, but did not reach statistical significance in 4 of 5 assessments.
- 299 Considering the immunosuppressed subgroup, the directionality and significance of our
- 300 findings remained unchanged across 4 of 5 sensitivity analyses. Summary statistics for age
- were reported in 1291 nosocomial (mean 77.2 years), and 4542 community-acquired
- 302 COVID-19 (mean 70.1 years) admissions. Gender was available in 1313 nosocomial (49.7%
- 303 male) and 4375 (56.6% male) community-acquired COVID-19 cases. These differences
- 304 precluded meta-regression analysis.

#### 3.8 Reporting biases

- We assessed for publication bias by examining the cumulative evidence distribution for our
- primary outcome using a funnel plot (Figure 5). Egger's test did not suggest funnel plot
- asymmetry (p=0.51). Given the potentially sensitive implications of nosocomial infection
- 309 (48), we hypothesised selective reporting of mortality might exist between nations. We
- 310 therefore compared the frequency and origin of reports identified at the full text eligibility
- 311 review stage meeting our study definition of a nosocomial outbreak (n= 67), with those
- 312 including mortality as an outcome within this patient group independent of community

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

outcomes. Overall 38 studies included mortality as an outcome (including 5 studies without observed nosocomial deaths), equating to a mortality reporting rate of 57%. Table 5 shows variation in the rate of mortality reporting by country. Reports from the UK accounted for 21/67 (31%) of nosocomial reports, and included mortality an outcome in 15/21 (71%). By contrast, reports from the United States contributed 7/67 (10%) of international reports describing nosocomial outbreaks, however none reported mortality as an outcome measure. This deviated significantly from the predicted international reporting rate (Fisher's exact test, p = 0.0018). Together, this suggests publication bias may be present. **Figure 5: Funnel Plot** Table 5: Rates of mortality reporting in nosocomial COVID-19 outbreaks, by country of origin 3.9 Certainty of evidence We assessed the quality of evidence supporting the statement: "In the general adult population, nosocomial COVID-19 is associated with a greater risk of inpatient mortality compared to individuals hospitalised with community-acquired COVID-19" as very low; and low/moderate in relation to "In an immunosuppressed adult population, nosocomial COVID-19 is associated with a greater risk of inpatient mortality compared to individuals hospitalised with community-acquired COVID-19". Full GRADE assessment is shown in Table 6. Table 6: Grading of Recommendations, Assessment, Development and Evaluations (GRADE) assessment

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

4 **Discussion** In this systematic review and meta-analysis addressing the burden of nosocomial COVID-19, we show the case fatality rate for nosocomial COVID-19 appears greater than communityacquired COVID-19, with a relative risk of 1.31 (95% CI: 1.01 to 1.70). Strikingly, we found that patients with malignancy (11,37) or transplant recipients (33) had approximately double the risk of dying after acquiring COVID-19 in hospital, compared to those hospitalised with community-acquired infection. This equates to a crude absolute mortality rate of 50.7% vs 23.8% respectively, with a consistent effect across studies and proved robust to sensitivity analyses assessing multiple assumptions around the certainty of nosocomial COVID-19 diagnosis and study quality. The convergence of widely recognized risk factors for adverse outcomes in communityacquired COVID-19 in hospitalised patient groups, such as advanced age and frailty, are likely to contribute to the exaggerated mortality burden observed with nosocomial COVID-19. A range of potential mechanisms are likely to link individuals with cancer or recipients of with mortality risk from nosocomial COVID-19, including transplants immunosuppression linked to the underlying condition and/or treatments and exposure due to health care requirements necessitating admission to the acute hospital environment. This is convergent with the heightened risk of mortality from COVID-19 independently reported for individuals with inherited and acquired forms of immunodeficiency (16), and the wider susceptibility of patients with haematological malignancy across a spectrum of healthcareassociated infections (49). Individual studies suggested a relationship between mortality rates and degree of immunosuppression, with the greatest mortality rate observed in patients with haematological malignancies who had recently received chemotherapy (37). This is consistent with results from patients enrolled within the UK Coronavirus Cancer Monitoring Project, which included 227 patients with haematological malignancies diagnosed with COVID-19. In this setting, recent chemotherapy approximately doubled the odds of dying during COVID-19-associated hospital admission (odds ratio: 2.09; 95% CI 1.09 to 4.08) after adjusting for age and gender; however, this study did not account for nosocomial infection. Our study has several strengths. We systematically screened both the peer-reviewed and preprint literature, leveraging the enhanced availability of full-texts by many publishers, to summarise the outcomes of 8246 adults hospitalised with COVID-19 during the first wave of

the pandemic across 8 countries. This work establishes a relevant baseline for subsequent and

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

future waves of the COVID-19 pandemic, and to our knowledge, represents the first metaanalysis of nosocomial COVID-19 mortality rates published to date. Zhou et al reported a rapid review and meta-analysis of nosocomial infections due to a range of viral pandemic threats, but included only 3 studies with SARS-CoV-2 and did not consider mortality as an outcome (7). In order to support the generalisability of our findings, we included studies with implicit and explicit definitions of nosocomial COVID-19. Accordingly, we catalogued a wide spectrum of case definitions, including combined epidemiological and genomic viral sequencing (32). We controlled for this variation in case definitions within our sensitivity analyses, for instance utilising outcomes meeting consensus international criteria for definite nosocomial infection wherever available. Although our funnel plot did not indicate publication bias amongst studies reporting mortality, our sequential literature review process suggests variation in the frequency of mortality reporting associated with studies describing nosocomial COVID-19 outbreaks. In particular, we identified no studies reporting mortality associated with nosocomial COVID-19 infection outbreaks originating from the United States, despite the high rate of COVID-19 cases and mortality in this country to date (50). Of the 7 studies we identified reporting nosocomial COVID-19 at the full text review stage, four dealt only with incidence (51–54), whilst three reported mortality but without reference to probable origin (55–57). Whilst we cannot exclude the risk of reporting bias, given the sensitive nature of this topic (48), this observation highlights successful infection control practices. Reporting on experience from a large US academic medical centre, Rhee et al found that despite a high burden of COVID-19, only two patients likely acquired COVID-19 during their admission (51). Generalising these practices may constitute a challenge across global health care settings acutely, for instance shortages of negative pressure isolation rooms were reported during the first wave in UK hospitals (44), but remain relevant as part of a longer-term "rebuild better" strategy. Our study also has limitations, including its focus on hospitalised patients during the first wave of the pandemic. This is likely to introduce both selection and reporting bias, as during this period limited capacity meant RT-PCR testing was initially restricted to symptomatic individuals in the community (40,41). Estimates of age-stratified infection fatality rates in the adult UK general population during the first wave ranged from 0.03% (20-29 years) to 7.8% (over 80 years) (58), far lower than the inpatient comparator mortality rate used in our analysis. By contrast, individuals admitted during nosocomial outbreaks were more likely to be subject to screening, resulting in sampling of individuals across the true spectrum of

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

disease severities (34,44), including earlier in their disease course. Our risk of bias assessment therefore focused on study inclusion and adequate follow-up as essential domains, to account for unequal disease progression at study entry between groups. Taken together, this considerably strengthens evidence for the statement: "nosocomial COVID-19 was associated with a greater risk of mortality, compared to individuals with community-acquired COVID-19 in the general adult population during the first wave of the COVID-19 pandemic". Due to limitations in the summary data available, we were unable to perform planned meta-regression for factors such as age, gender, frailty, ethnicity or deprivation. Similarly, as studies typically reported all-cause mortality, we cannot exclude that deaths may have occurred that were not directly linked to COVID-19. However, our findings are supported by examination of COVID-19-linked mortality data within the United Kingdom (59,60), which indicate that COVID-19 multiplies the risk of death associated with various underlying diagnoses (59). In conclusion, we systematically gathered data from the international literature and demonstrate an increased relative risk of mortality associated with nosocomial and community COVID-19. This maybe underestimated due to consideration of only hospitalised individuals. In particular, we strengthen observational evidence indicating individuals with malignancy or transplant recipients are at markedly elevated risk of death when infected by SARS-CoV-2 in hospital, compared to the community. Although focusing on the first wave, our findings are likely of ongoing significance given confirmation of an impaired SARS-CoV-2 vaccine response in multiple immunosuppressed patient groups (61–63), and the continued occurrence of new viral variants with enhanced transmissibility. Together, these findings inform policy makers by strongly advocating continued public health surveillance, stringent infection control measures (51), and access to individualised clinical interventions (64,65) to combat the threat of nosocomial COVID-19.

5 Conflict of Interest

428

- 429 All authors declare that the research was conducted in the absence of any commercial or
- financial relationships that could be construed as a potential conflict of interest.

#### 431 **6 Author Contributions**

- 432 MJP conceived the project and drafted the protocol with TJCW and SS, with supervision
- 433 from SB, SJ, IH, and DF. MJP, SS, TJCW, KO, CD, and DS screened abstracts and
- performed the full text review. MJP, TJCW and SS performed the data quality assessment.
- 435 TJCW and MJP analysed the data. MJP prepared the first draft of the manuscript. All authors
- contributed to manuscript revision, read, and approved the submitted version.

# **437 7 Funding**

- 438 This work was partly funded by UKRI/NIHR through the UK Coronavirus Immunology
- Consortium (UK-CIC). MJP is supported by the Welsh Clinical Academic Training (WCAT)
- programme and a Career Development Award from the Association of Clinical Pathologists
- and is a participant in the NIH Graduate Partnership Program. IH is a Wellcome Trust Senior
- 442 Research Fellow in Basic Biomedical Sciences. The funding sources did not have any role in
- designing the study, performing analysis or communicating findings.

#### 444 **8** Ethical approval

- 445 The data used in this work obtained relevant participant consent and ethical approval,
- therefore no additional approvals were required.

#### 447 **9** Patient and public involvement

- No patients or participants were involved in setting the research question or the outcome
- measures, nor were they involved in developing plans for design or implementation of the
- 450 study. No patients were asked to advise on interpretation or writing up of results. The
- 451 published manuscript relating to this work will be sent to the UK Coronavirus Immunology
- 452 Consortium (UKCIC) for appropriate dissemination to participants.

#### 10 Supplementary Material

453

454 Supplementary Materials are available online.

#### 11 Data Availability Statement

- 456 The datasets analysed for this study will be made available upon written request to the
- 457 corresponding author.
- 458 12 References

- 459 1. Burke JP. Infection Control A Problem for Patient Safety. New England Journal of
- 460 Medicine. 2003;348(7):651–6.
- 461 2. Allegranzi B, Nejad SB, Combescure C, Graafmans W, Attar H, Donaldson L, et al.
- Burden of endemic health-care-associated infection in developing countries: systematic
- 463 review and meta-analysis. The Lancet. 2011;377(9761):228–41.
- Senior K. Can we keep up with hospital-acquired infections? The Lancet Infectious
- 465 Diseases. 2001;1:8.
- 466 4. Godoy P, Torner N, Soldevila N, Rius C, Jane M, Martínez A, et al. Hospital-acquired
- 467 influenza infections detected by a surveillance system over six seasons, from 2010/2011 to
- 468 2015/2016. BMC Infectious Diseases. 2020 Jan 28;20(1):80.
- 469 5. NHS England and NHS Improvement, Chief Executives and Chief Operating Officers
- 470 of all NHS Trusts and Foundation Trusts, CCG Accountable Officers. Minimising
- 471 nosocomial infections in the NHS. 2020.
- 472 6. Bak A, Mugglestone MA, Ratnaraja NV, Wilson JA, Rivett L, Stoneham SM, et al.
- 473 SARS-CoV-2 routes of transmission and recommendations for preventing acquisition: joint
- 474 British Infection Association (BIA), Healthcare Infection Society (HIS), Infection Prevention
- 475 Society (IPS) and Royal College of Pathologists (RCPath) guidance. Journal of Hospital
- 476 Infection [Internet]. [cited 2021 Jun 24]; Available from:
- 477 https://doi.org/10.1016/j.jhin.2021.04.027
- 478 7. Zhou Q, Gao Y, Wang X, Liu R, Du P, Wang X, et al. Nosocomial infections among
- patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann Transl
- 480 Med. 2020;8(10):629–629.
- 481 8. PHE; LSHTM; The contribution of nosocomial infections to the first wave. Scientific
- 482 Advisory Group for Emergencies (SAGE) [Internet]. 2021 Feb 12; Available from:
- https://www.gov.uk/government/publications/phe-and-lshtm-the-contribution-of-nosocomial-
- 484 infections-to-the-first-wave-28-january-2021
- Ponsford MJ, Jefferies R, Davies C, Farewell D, Humphreys IR, Jolles S, et al. The
- burden of nosocomial covid-19 in Wales: results from a multi-centre retrospective
- observational study of 2508 hospitalized adults. Thorax. 2021 Jun 18;manuscript in press.
- 488 10. Lee J. Y, Kim H. A, Huh K, Hyun M, Rhee J. Y, Jang S, et al. Risk Factors for
- 489 Mortality and Respiratory Support in Elderly Patients Hospitalized with COVID-19 in Korea.
- 490 J Korean Med Sci. 2020;35(23):e223.

- 491 11. Elkrief A, Desilets A, Papneja N, Cvetkovic L, Groleau C, Lakehal Y. A, et al. High
- 492 mortality among hospital-acquired COVID-19 infection in patients with cancer: A
- 493 multicentre observational cohort study. European Journal of Cancer. 2020;139:181–7.
- 494 12. Carter B, Collins JT, Barlow-Pay F, Rickard F, Bruce E, Verduri A, et al. Nosocomial
- 495 COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial Study
- 496 (COVID in Older PEople). Journal of Hospital Infection. 2020;106(2):376–84.
- 497 13. Khan KS, Reed-Embleton H, Lewis J, Saldanha J, Mahmud S. Does nosocomial
- 498 SARS-CoV-2 infection result in increased 30-day mortality? A multi-centre observational
- 499 study to identify risk factors for worse outcomes in COVID-19 disease. J Hosp Infect. 2020
- 500 Sep 17;107:91–4.
- 501 14. Richterman A, Meyerowitz E. A, Cevik M. Hospital-Acquired SARS-CoV-2
- 502 Infection: Lessons for Public Health. JAMA Journal of the American Medical Association.
- 503 2020;324(21):2155–6.
- 504 15. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors
- associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug
- 506 1;584(7821):430–6.
- 507 16. Shields AM, Burns SO, Savic S, Richter AG, Anantharachagan A, Arumugakani G, et
- al. COVID-19 in patients with primary and secondary immunodeficiency: The United
- 509 Kingdom experience. Journal of Allergy and Clinical Immunology.
- 510 17. Khalid U, Ilham MA, Nagaraja P, Elker D, Asderakis A. SARS-CoV-2 in Kidney
- Transplant and Waitlisted Patients During the First Peak: The Welsh Experience. Transplant
- 512 Proc. 2020/12/19 ed. 2021 May;53(4):1154–9.
- 513 18. Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, et al. The
- effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European,
- observational cohort study. The Lancet Public Health. 2020;5(8):e444–51.
- 516 19. Richards SJG, D'Souza J, Pascoe R, Falloon M, Frizelle FA. Prevalence of frailty in a
- tertiary hospital: A point prevalence observational study. PLOS ONE. 2019;14(7):e0219083–
- 518 e0219083.
- 519 20. Page MJ, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, et al. The
- 520 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021
- 521 Mar 29;372:n71.
- 522 21. Bandyopadhyay S, Baticulon RE, Kadhum M, Alser M, Ojuka DK, Badereddin Y, et
- al. Infection and mortality of healthcare workers worldwide from COVID-19: a systematic
- review. BMJ Global Health. 2020 Dec 1;5(12):e003097.
- 525 22. Abbas M, Robalo Nunes T, Martischang R, Zingg W, Iten A, Pittet D, et al.
- Nosocomial transmission and outbreaks of coronavirus disease 2019: the need to protect both
- 527 patients and healthcare workers. Antimicrobial Resistance and Infection Control.
- 528 2021;10(1):7.
- 529 23. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile
- app for systematic reviews. Systematic Reviews. 2016 Dec 5;5(1):210.

- 531 24. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K. Chapter 7: Systematic reviews
- of etiology and risk. In: Joanna Briggs Institute Reviewer's Manual.
- 533 https://reviewersmanual.joannabriggs.org/;
- 534 25. NICE. Appendix H: Appraisal checklists, evidence tables, GRADE and economic
- profiles. In: Developing NICE guidelines: the manual. (Process and methods [PMG20]).
- 536 26. Langan D, Higgins JPT, Jackson D, Bowden J, Veroniki AA, Kontopantelis E, et al.
- A comparison of heterogeneity variance estimators in simulated random-effects meta-
- analyses. Research synthesis methods. 2019 Mar;10(1):83–98.
- 539 27. Perera R, Heneghan C. Interpreting meta-analysis in systematic reviews. Evid Based
- 540 Med. 2008 Jun 1;13(3):67.
- 541 28. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV. Cochrane
- Handbook for Systematic Reviews of Interventions. Cochrane. 2021; version 6.
- 543 29. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
- 544 analyses. BMJ. 2003 Sep 6;327(7414):557–60.
- 545 30. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.
- 546 GRADE: an emerging consensus on rating quality of evidence and strength of
- 547 recommendations. BMJ. 2008;336(7650):924–6.
- 548 31. Vanhems P, Saadatian-Elahi M, Chuzeville M, Marion E, Favrelle L, Hilliquin D, et
- al. Rapid nosocomial spread of SARS-CoV-2 in a French geriatric unit. Infect Control Hosp
- 550 Epidemiol. 2020;41(7):866–7.
- 551 32. Snell LB, Fisher CL, Taj U, Merrick B, Alcolea-Medina A, Charalampous T, et al.
- 552 Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 transmission
- identifies community social distancing as the dominant intervention reducing outbreaks.
- 554 medRxiv. 2020;2020.11.17.20232827.
- 555 33. Coll E, Fernandez-Ruiz M, Sanchez-Alvarez J. E, Martinez-Fernandez J. R, Crespo
- M, Gayoso J, et al. Covid-19 in transplant recipients: the spanish experience. American
- 557 journal of transplantation □: official journal of the American Society of Transplantation and
- the American Society of Transplant Surgeons. 2020;
- 559 34. Davis P, Gibson R, Wright E, Bryan A, Ingram J, Lee RP, et al. Atypical
- 560 presentations in the hospitalized older adult testing positive for SARS-CoV-2: a retrospective
- observational study in Glasgow, Scotland. Scott Med J. 2020 Oct 11;36933020962891.
- 562 35. Garatti A, Castelvecchio S, Daprati A, Molfetta R, Volpe M, De Vincentiis C, et al.
- 563 Clinical Course of COVID-19 Infection in Patients Urgently Operated of Cardiac Surgical
- 564 Procedures. Annals of surgery. 2020;272(4):e275–9.
- 565 36. Ajayi B, Trompeter A, Arnander M, Sedgwick P, Lui DF. 40 days and 40 nights:
- 566 Clinical characteristics of major trauma and orthopaedic injury comparing the incubation and
- lockdown phases of COVID-19 infection. Bone & joint open. 2020;1(7):330–8.
- 568 37. Bhogal T, Khan U. T, Lee R, Stockdale A, Hesford C, Potti-Dhananjaya V, et al.
- 569 Haematological malignancy and nosocomial transmission are associated with an increased

- 570 risk of death from COVID-19: results of a multi-center UK cohort. Leukemia and
- 571 Lymphoma. 2021;
- 572 38. Brill SE, Jarvis HC, Ozcan E, Burns TLP, Warraich RA, Amani LJ, et al. COVID-19:
- a retrospective cohort study with focus on the over-80s and hospital-onset disease. BMC
- 574 Med. 2020 Jun 25;18(1):194.
- 575 39. Gonfiotti A, Gatteschi L, Salvicchi A, Bongiolatti S, Lavorini F, Voltolini L. Clinical
- 576 courses and outcomes of five patients with primary lung cancer surgically treated while
- affected by Severe acute respiratory syndrome coronavirus 2. European journal of cardio-
- 578 thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery.
- 579 2020;58(3):598–604.
- 580 40. Jewkes SV, Zhang Y, Nicholl DJ. Nosocomial spread of COVID-19: Lessons learned
- from an audit on a stroke/neurology ward in a UK district general hospital. Clinical Medicine,
- Journal of the Royal College of Physicians of London. 2020;20(5):E173–7.
- Wake RM, Morgan M, Choi J, Winn S. Reducing nosocomial transmission of
- 584 COVID-19: implementation of a COVID-19 triage system. Clin Med (Lond). 2020
- 585 Sep;20(5):e141–5.
- 586 42. Harada S, Uno S, Ando T, Iida M, Takano Y, Ishibashi Y, et al. Control of a
- Nosocomial Outbreak of COVID-19 in a University Hospital. Open Forum Infect Dis. 2020
- 588 Dec;7(12):ofaa512.
- 589 43. Cao J, Tu W. -J, Cheng W, Yu L, Liu Y. -K, Hu X, et al. Clinical features and short-
- term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China. Clinical
- 591 Infectious Diseases. 2020;71(15):748–55.
- 592 44. Khonyongwa K, Taori SK, Soares A, Desai N, Sudhanva M, Bernal W, et al.
- 593 Incidence and outcomes of healthcare-associated COVID-19 infections: significance of
- delayed diagnosis and correlation with staff absence. J Hosp Infect. 2020 Dec;106(4):663–72.
- 595 45. Sanchez M. D, Sanchez M, De La Morena J. M, Ogaya-Pinies G, Mateo E,
- Moscatiello P, et al. Nosocomial SARS-CoV-2 infection in urology departments: Results of a
- 597 prospective multicentric study. International Journal of Urology. 2021;28(1):62–7.
- 598 46. Lakhani K, Minguell J, Guerra-Farfan E, Lara Y, Jambrina U, Pijoan J, et al.
- Nosocomial infection with SARS-CoV-2 and main outcomes after surgery within an
- orthopaedic surgery department in a tertiary trauma centre in Spain. International
- 601 Orthopaedics. 2020;44(12):2505–13.
- 602 47. Pellaud C, Grandmaison G, Thien H. P.P.H, Baumberger M, Carrel G, Ksouri H, et al.
- 603 Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients
- 604 hospitalized with COVID-19 in a Swiss area A retrospective cohort study. Swiss Medical
- 605 Weekly. 2020;150(29):w20314.
- 606 48. Barranco R, Du Tremoul LVB, Ventura FA. Hospital-acquired sars-cov-2 infections
- 607 in patients: Inevitable conditions or medical malpractice? International Journal of
- 608 Environmental Research and Public Health. 2021;18(2):1–9.

- 609 49. Liu H, Zhao J, Xing Y, Li M, Du M, Suo J, et al. Nosocomial Infection in Adult
- 610 Admissions with Hematological Malignancies Originating from Different Lineages: A
- Prospective Observational Study. PLOS ONE. 2014 Nov 21;9(11):e113506.
- 50. Johns Hopkins Center for Systems Science and Engineering. The Johns Hopkins
- 613 Coronavirus Resource Center (CRC).
- 614 51. Rhee C, Baker M, Vaidya V, Tucker R, Resnick A, Morris CA, et al. Incidence of
- Nosocomial COVID-19 in Patients Hospitalized at a Large US Academic Medical Center.
- 616 JAMA Network Open. 2020;3(9):e2020498.
- 52. Long D. R, O'Reilly-Shah V, Rustagi A. S, Bryson-Cahn C, Jerome K. R, Weiss N.
- S, et al. Incidence of health care-associated COVID-19 during universal testing of medical
- and surgical admissions in a large US health system. Open Forum Infectious Diseases.
- 620 2020;7(10).
- 53. Thompson JWJ, Mikolajewski AJ, Kissinger P, McCrossen P, Smither A, Chamarthi
- 622 GD, et al. An Epidemiologic Study of COVID-19 Patients in a State Psychiatric Hospital:
- 623 High Penetrance With Early CDC Guidelines. Psychiatric services (Washington, DC).
- 624 2020;71(12):1285–7.
- 625 54. Nalleballe K, Siddamreddy S, Kovvuru S, Veerapaneni P, Roy B, Onteddu S. R. Risk
- of COVID-19 from hospital admission during the pandemic. Infect Control Hosp Epidemiol.
- 627 2020:
- 628 55. Mani V. R, Kalabin A, Valdivieso S. C, Murray-Ramcharan M, Donaldson B. New
- 629 York inner city hospital COVID-19 experience and current data: Retrospective analysis at the
- 630 epicenter of the American coronavirus outbreak. Journal of Medical Internet Research.
- 631 2020;22(9):e20548.
- 632 56. Dowlati E, Zhou T, Sarpong K, Pivazyan G, Briscoe J, Fayed I, et al. Case Volumes
- and Perioperative Coronavirus Disease 2019 Incidence in Neurosurgical Patients During a
- Pandemic: Experiences at Two Tertiary Care Centers in Washington, DC. World
- 635 Neurosurgery. 2020 Nov;143:e550–60.
- 636 57. Hu P, Jansen J. O, Uhlich R, Black J, Pierce V, Hwang J, et al. Early comprehensive
- 637 testing for COVID-19 is essential to protect trauma centers. Journal of Trauma and Acute
- 638 Care Surgery. 2020;89(4):698–702.
- 639 58. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of
- the severity of coronavirus disease 2019: a model-based analysis. The Lancet Infectious
- 641 Diseases. 2020;20(6):669–77.
- 642 59. Bhaskaran K, Bacon S, Evans SJ, Bates CJ, Rentsch CT, MacKenna B, et al. Factors
- associated with deaths due to COVID-19 versus other causes; population-based cohort
- analysis of UK primary care data and linked national death registrations within the
- OpenSAFELY platform. The Lancet Regional Health Europe [Internet]. 2021 Jul 1 [cited
- 646 2021 Jun 24];6. Available from: https://doi.org/10.1016/j.lanepe.2021.100109
- 647 60. Salmon R. L, Monaghan S. P. AO Salmon R.L, ORCID: http://orcid. org/---. Who is
- 648 dying from COVID-19 in the United Kingdom? A review of cremation authorisations from a
- single South Wales' crematorium. Epidemiology and Infection. 2021;

- 650 61. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al.
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ
- 652 Transplant Recipients. JAMA. 2021 Jun 1;325(21):2204–6.
- 653 62. Parry HM, McIlroy G, Bruton R, Ali M, Stephens C, Damery S, et al. Antibody
- Responses After First and Second COVID-19 Vaccination in Patients With Chronic
- 655 Lymphocytic Leukaemia. 2021; Available from:
- http://europepmc.org/abstract/PPR/PPR348446
- 657 63. Wadei HM, Gonwa TA, Leoni JC, Shah SZ, Aslam N, Speicher LL. COVID 19
- infection in solid organ transplant recipients after SARS \( \) CoV \( \) 2 vaccination. American
- 659 journal of transplantation. 2021;

- 660 64. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an
- mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med [Internet].
- 2021 Jun 23 [cited 2021 Jun 25]; Available from: https://doi.org/10.1056/NEJMc2108861
- 663 65. Horby, W P, Mafham M, Peto L, Campbell M, Pessoa-Amorim G, et al. Casirivimab
- and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a
- randomised, controlled, open-label, platform trial. medRxiv [Internet]. 2021; Available from:
- 666 https://www.medrxiv.org/content/early/2021/06/16/2021.06.15.21258542

669 13 Tables and Figures accompanying main article

13.1 Table 1: Evidence Summary Table

670

Reference	Study type	Country	Study population and setting	Study period	Nosocomial case definition	Number of participants (%)†, *	Mortality (%) <sup>†</sup>	Critical care admission	Length of follow-up
Ajayi et al <sup>36</sup>	Retrospective cohort	UK	39 hospitalized adult trauma patients with RT-PCR diagnosis of COVID-19 admitted to London centre.	26/1/20 to 14/4/20 (80 days)	No explicit definition.	Community: 12 (30.8%) Nosocomial: 27 (69.2%)	Community: 1 (8.3%) Nosocomial: 7 (25.9%)	Not reported.	Until death or discharge.
Bhogal et al <sup>37</sup>	Retrospective cohort	UK	179 hospitalized adult cancer patients with RT-PCR diagnosis of COVID-19 across 6 hospitals in England.	1/3/20 to 10/6/20 (102 days)	"Probable": 8-14 days.  "Definite": > 14 days following admission	Community: 145 (82.8%)  Nosocomial: 28 (16.2%)	Community: 36 (24.8%) Nosocomial: 18 (64.3%)	Not reported.	Until discharge, death, or last available follow- up 17/6/20 (minimum 7 days; median 44).
Brill et al <sup>38</sup>	Retrospective	UK	450 hospitalized adults with RT-PCR diagnosis of COVID- 19 in London teaching hospital	10/3/20 to 8/4/20 (30 days)	RT-PCR diagnosis made >14 days following continuous admission.	Community: 419 (93.1%) Nosocomial: 31 (6.9%)	Community: 166 (39.6%) Nosocomial: 7 (22.6%)	Not reported.	Until death or discharge.
Cao et al <sup>43</sup>	Retrospective	China	78 adults hospitalized with laboratory-confirmed COVID- 19 in Wuhan (24 healthcare workers excluded)	3/1/20 to 1/2/20 (30 days)	Close contact with known positive case whilst admitted to hospital or outpatient visit in last 14 days	Community: 68 (87.2%) Nosocomial: 10 (12.8%)	Community: 15 (22.1%) Nosocomial: 2 (20.0%)	Not reported.	Until death or discharge, until 15/2/20 (minimum 14 days).

Carter et al <sup>12</sup>	Prospective cohort	UK and Italy	1564 hospitalized adults with laboratory-confirmed COVID- 19 across 10 UK and 1 Italian hospitals	27/2/20 to 28/4/20 (62 days)	"Definite": > 14 days from admission to diagnosis.	Community:  1368 (87.5%)  Nosocomial:  196 (12.5%)	Community: 372 (27.2%) Nosocomial: 53 (27.0%)	Not reported.	Until death or discharge (minimum 7 days).
Coll et al <sup>33</sup>	Retrospective case series	Spain	778 solid organ transplant and hematopoietic stem cell transplant recipients with clinical-laboratory COVID-19 diagnosis across 61 Spanish transplant centres.	20/2/20 to 13/7/20 (145 days)	No explicit definition given.	Community: 679 (87.3%) Nosocomial: 99 (12.7%)	Community*:  133 of 570 (23.3%)  Nosocomial*:  37 of 77 (48.1%)	Not reported.	Not explicitly defined.  *Outcome data available in 647 only.
Davis et al <sup>34</sup>	Retrospective cohort	UK	222 hospitalized adults with a RT-PCR confirmed diagnosis of COVID-19 within department of medicine for elderly across 3 Scottish (UK) hospitals	18/3/20 to 20/4/20 (34 days)	RT-PCR diagnosis made >14 days following admission.	Community: 119 (53.6%) Nosocomial: 103 (46.4%)	Community: 54 (45.4%) Nosocomial: 41 (39.8%)	Community: 0 (0.0 %) Nosocomial: 4 (3.9%)	30 day mortality following date of RT- PCR testing
Elkrief et al <sup>11</sup>	Prospective cohort	Canada	249 hospitalized adults with cancer and a laboratory- confirmed diagnosis of COVID-19 (3 children excluded)	3/3/20 to 23/5/20 (82 days)	Diagnosis of COVID- 19 >6 days after unrelated admission.	Community: 202 (81.1%)  Nosocomial: 47 (18.9%)	Community: 49 (24.3%)  Nosocomial: 22 (46.8%)	Community: 27 (13.4%)  Nosocomial: 6 (12.8%)	Until death or last follow-up (median 25 days).
Garatti et al <sup>35</sup>	Retrospective case series	Italy	10 hospitalized adults undergoing urgent cardiac surgery in Italian with a clinical	21/2/20 to 08/03/20	Clinical diagnosis made > 8 days	Community:	Community:	Community:	Until death or discharge (median 25 days post

			diagnosis of COVID-19	(17 days)	following admission.	4 (40%)	1 (25.0%)	1 (25.0%)	symptom onset).
						Nosocomial:	Nosocomial:	Nosocomial:	
						6 (60%)	0 (0.0%)	0 (0.0%)	
Gonfiotti et al 39	Retrospective case series	Italy	5 adult patients hospitalized in Italian thoracic surgery unit	29/1/20 to 4/3/20	Close contact with known positive case	Community:	Community:	Community:	Until death or discharge (21-60 days post
			with a RT-PCR confirmed diagnosis of COVID-19.	(36 days)	whilst in hospital (no explicit interval	1 (20.0%)	0 (0.0%)	0 (0.0%)	surgery).
				(30 days)	defined).		Nosocomial:	Nosocomial:	
						4 (80.0%)	2 (50.0%)	1 (25.0%)	
Harada et al <sup>42</sup>	Prospective cohort	Japan	562 patients tested prior or during hospitalization to	24/3/20 to 24/4/20	Development of symptoms and RT-	Community:	Community:	Community:	Not explicitly defined
	Conort		Japanese university hospital following nosocomial outbreak.	(32 days)	PCR test >5 days following admission.	19 (79.2%)	1 (5.3%)	4 (21.1%)	
			,	(32 days)	<i>3 3</i>	Nosocomial:	Nosocomial:	Nosocomial:	
						5 (20.8%)	3 (60.0%)	1 (20.0%)	
Jewkes et al 40	Retrospective case series	UK	133 adults admitted to an acute stroke unit within the UK with	12/3/20 to 5/5/20	Development of symptoms and RT-	Community:	Community:	Not reported.	Not explicitly defined
	cuse series		nosocomial COVID-19 outbreak.	(54 days)	PCR test >14 days following admission.	13 (61.9%)	7 (53.8%)	reported.	
			outer cann	(34 days)	Tono wing udinission	Nosocomial:	Nosocomial:		
						8 (38.1%)	3 (37.5%)		
Khan et al 13	Prospective cohort	UK	173 adults hospitalized within 3 acute Scottish (UK) hospitals	9/4/20 to 9/5/20	RT-PCR diagnosis made >7 days	Community:	Community:	Community:	30 day outcomes from admission or diagnosis,
	Conort		with an RT-PCR confirmed COVID-19 on 9/4/20.	(30 days)	following admission.	154 (89.0%)	28 (18.2%)	46 (29.9%)	censored at discharge.
				(2.2.20)		Nosocomial:	Nosocomial:	Nosocomial:	
						19 (11.0%)	4 (21.1%)	2 (10.5%)	

Khonyongwa et al <sup>44</sup>	Retrospective cohort (prevalence)	UK	856 adults hospitalized for at least an overnight stay with RT-PCR confirmed COVID-19 within a London (UK) hospital, and no recent admission.	1/3/20 to 18/4/20 (48 days)	Development of symptoms and RT- PCR test >14 days following admission for non-COVID-19 indication.	Community: 716 (92.5%)  Nosocomial: 58 (7.5%)	Community: 187 (26.1%) Nosocomial: 15 (25.9%)	Community: 232 (32.4%)  Nosocomial: 13 (22.4%)	30 day outcomes
Lakhani et al <sup>46</sup>	Retrospective case series (prevalence)	Spain	288 hospitalized adult trauma patients with RT-PCR confirmed COVID-19 admitted to Spanish (UK) centre.	9/3/20 to 4/5/20 (57 days)	Development of symptoms and RT- PCR test >4 days following admission and <14 days of discharge for non- COVID-19 indication.	Community: 10 (34.5%) Nosocomial: 19 (65.5%)	Community: 5 (50.0%) Nosocomial: 7 (36.8%)	Not reported.	Minimum 14-days after discharge
Lee et al <sup>10</sup>	Retrospective cohort.	Spain	98 adults aged ≥ 65 years hospitalized with RT-PCR confirmed COVID-19 to 4 Korean hospitals.	18/2/20 to 4/3/20 (16 days)	Diagnosis of COVID- 19 during admission for unrelated illness.	Community: 86 (87.8%) Nosocomial: 12 (12.2%)	Community: 13 (15.1%) Nosocomial: 7 (58.3%)	Community: 14 (16.3%) Nosocomial: 2 (16.7%)	Death or discharge (minimum 14-days following admission)
Pellaud et al <sup>47, ±</sup>	Retrospective cohort	Switzerland	196 patients hospitalized with laboratory confirmed COVID- 19 across 5 hospitals within Fribourg region.	1/3/20 to 12/4/20 (43 days)	No explicit definition reported.	Community: 183 (93.4%) Nosocomial: 13 (6.6%)	Not reported	Community: 49 (26.8%) Nosocomial: 0 (0%)	30 days after onset of symptoms
Ponsford et al <sup>9</sup>	Retrospective cohort	UK	2508 hospitalized adults with RT-PCR diagnosis of COVID- 19 across 18 hospitals in Wales	1/3/20 to 1/6/20	"Probable": > 7 days  "Definite": > 14 days from admission to	Community:	Community: 585 (32.8%)  Nosocomial:	Not reported.	Until death or discharge, until 20/11/20 (minimum

			(UK)	(123 days)	diagnosis (multiple considered)	(71.1%)  Nosocomial: 724 (28.9%)	300 (41.4%)		follow-up 142 days).
Sanchez et al <sup>45</sup>	Prospective cohort (prevalence)	Spain	143 adults admitted for urological surgery within 2 Spanish hospitals.	9/3/20 to 3/5/20 (56 days)	Development of symptoms ≥3 days of surgery and within 14 days of discharge.	Community: 2 (40.0%) Nosocomial: 3 (60.0%)	Community: 1 (50.0%) Nosocomial: 0 (0.0%)	Community: 1 (50.0%) Nosocomial: 0 (0.0%)	14-days following hospital discharge.
Snell et al <sup>32</sup>	Prospective cohort	UK	574 consecutive adults hospitalized with RT-PCR confirmed COVID-19 to single London (UK) hospital.	13/3/20 to 31/3/20 (19 days)	"Probable": > 7 days  "Definite": > 14 days from admission to diagnosis; additional viral genomic and epidemiological analysis.	Community: 462 (83.7%) Nosocomial: 90 (16.3%)	Community: 78 (16.9%) Nosocomial: 32 (35.6%)	Not reported.	Death or discharge (duration unclear).
Vanhems et al <sup>31</sup>	Retrospective case series	France	7 adults hospitalized with RT-PCR confirmed COVID-19 to 24-bed geriatric ward within Lyon region.	29/2/20 to 14/3/20 (15 days)	No explicit definition reported.	Community: 2 (28.6%) Nosocomial: 5 (71.4%)	Community: 1 (50.0%) Nosocomial: 1 (20.0%)	Community: 0 (0.0%)  Nosocomial: 0 (0.0%)	Death or discharge (including transfer to other hospitals)
Wake et al <sup>41</sup>	Prospective cohort (prevalence)	UK	662 adults hospitalized with RT-PCR confirmed COVID-19 to London hospital trust.	11/3/20 to 12/5/20 (63 days)	"Probable": > 7 days  "Definite": > 14 days from admission to diagnosis	Community: 573 (92.7%) Nosocomial: 45 (7.3%)	Community: 208 (36.3%)  Nosocomial: 14 (31.1%)	Community: Not reported Nosocomial: 2 (4.4%)	Unclear (median length of stay stated as 33 days, IQR 22-55).

673	Assumed to include end	date unless	otherwise s	pecified by authors
-----	------------------------	-------------	-------------	---------------------

- † In event of multiple case definitions for nosocomial infection, "probable" and "definite" case are both included.
- \* Healthcare workers and children were excluded wherever reported separately to patients (age ≥ 16 years).
- <sup>±</sup> Data only included within secondary meta-analysis.

# 13.2 Table 2: Risk of Bias Assessment - cohort studies (n=8)

677

678

Study	Domain 1*	Domain 2*	Domain 3*	Domain 4	Domain 5	Domain 6	Domain 7*	Domain 8*	Total Score
Ajayi et al	1	1	1	0	0	1	0	0	4
Brill et al	1	1	1	0	0	1	1	0	5
Lee et al	1	1	1	0	0	1	0	1	5
Bhogal et al	1	1	1	0	1	1	1	0	6
Elkrief et al	1	1	1	0	1	1	1	0	6
Carter et al	1	1	1	0	1	1	1	1	7
Khan et al	1	1	1	0	1	1	1	1	7
Ponsford et al	1	1	1	0	1	1	1	1	7

# 13.3 Table 3: Risk of bias assessment - prevalence studies (n=8)

Study	Domain 1*	Domain 2*	Domain 3*	Domain 4*	Domain 5	Domain 6	Domain 7*	Domain 8	Total Score
Jewkes et al	1	1	1	1	0	0	0	0	4
Wake et al	1	0	1	1	0	0	1	0	4
Sanchez et al	1	1	1	1	0	0	1	0	5
Harada et al	1	1	1	1	1	1	0	0	6
Davis et al	1	1	1	1	1	1	1	0	7
Cao et al	1	1	1	1	1	1	1	0	7
Khonyongwa et al	1	1	1	1	1	1	1	1	8

Lakhani et al	1	1	1	1	1	1	1	1	8

#### 13.4 Table 4: Risk of bias assessment - case series (n=5)

Study	Domain 1*	Domain 2*	Domain 3	Domain 4*	Domain 5	Domain 6	Domain 7	Domain 8*	Domain 9*	Domain 10	Total Score
Vanhems et al	1	0	0	0	0	1	1	1	0	0	4
Snell et al	1	1	1	1	0	0	0	1	1	0	6
Coll et al	1	0	1	0	0	1	1	0	1	1	6
Gonfiotti et al	0	1	1	1	0	1	1	1	1	0	7
Garatti et al	1	0	0	1	1	1	1	1	1	1	8

# Table 5: Rates of mortality reporting in nosocomial COVID-19 outbreaks, by country of origin

684

		al outbreak orted	Nosocomial	mortality reported as an outcome*
Country	Total studies, n	Total of studies (%)	Included studies, n	Fraction of countries' total reports
United Kingdom, UK	21	31%	15	71%
United States, US	7	10%	0	0%
China	6	9%	4	67%
Spain	5	7%	3	60%
France	3	4%	2	67%
Belgium	3	4%	0	0%
Italy	3	4%	2	67%
Switzerland	3	4%	1	33%
South Korea	2	3%	1	50%
Brazil	2	3%	2	100%
Japan	2	3%	2	100%
Vietnam	2	3%	0	0%
Germany	2	3%	1	50%
International	1	1%	1	100%
Poland	1	1%	1	100%
Denmark	1	1%	0	0%
India	1	1%	1	100%
Canada	1	1%	1	100%
Ireland	1	1%	1	100%
Total	67	-	38	57%

# 13.5 Table 6: Grading of Recommendations, Assessment, Development and Evaluations (GRADE) assessment


Statement	Number of studies and patients	Risk of bias	Indirectness	Inconsistency	Imprecision	Other considerations	Effect size	Overall quality of evidence
"In the general adult population, nosocomial COVID-19 is associated with a greater risk of inpatient mortality compared to individuals hospitalised with community-acquired COVID-19"	21 studies, 8246 patients. Probable nosocomial: 1517 Probable community: 6729	Serious - Very serious	Not serious	Very serious	Not serious	Publication bias suspected <sup>2</sup>	RR 1.31 95% CI: 1.01 to 1.70	Low/ very low
"In an immunosuppressed adult population, nosocomial COVID-19 is associated with a greater risk of inpatient mortality compared to individuals hospitalised with community-acquired COVID-19"	3 studies, 1069 patients.  Probable nosocomial: 152  Probable community: 917	Serious*	Not serious	Not serious	Serious <sup>1</sup>	Publication bias suspected <sup>2</sup> Strong association <sup>3</sup>	RR 2.14  95% CI: 1.76 to 2.61	Low/ Moderate

Created using GRADEPro online tool, https://gradepro.org/. \* All studies scored moderate/high in formal assessment, however follow-up duration was limited; <sup>1</sup> Significant uncertainty associated with heterogeneity assessment:  $I^2 = 0.00\%$ , 95% CI: 0.00 to 96.6%, downgrade by 1 level; <sup>2</sup> Mortality reporting bias suspected by country, downgrade by 1 level; <sup>3</sup> RR > 2.0 with consistent effect from  $\geq$ 2 studies, upgrade by 1 level.

# 13.6 Figure 1: PRISMA Study Flow Diagram

# Study Flow Diagram

692



695

696

697

698


699

700


701

# 13.7 Figure 2: Timing of UK studies relative to national COVID-19 rates

Plot showing the timing of individual studies included within the primary meta-analysis reporting patients within the United Kingdom (UK), relative to national daily COVID-19 case diagnosis rates January 2020 and April 2021. \* The study by Carter et al is included here as 10/11 hospital sites were within the UK.



# 13.8 Figure 3: Relative risk of mortality in hospitalized adults with nosocomial and community-acquired COVID-19



Forest plot assessing the relative risk (RR) and 95% confidence interval (95% CI) of mortality in adults hospitalized with community-acquired and probable nosocomial COVID-19, according to the study definitions. The size of each box is proportional to the size of the individual hospital site (A-N), with the error bars representing the 95% CIs. The diamond represents the pooled average across studies, based on a random effects (RE) model. I<sup>2</sup>: heterogeneity variance, calculated using restricted effects maximum likelihood (REML).

713

714

715

716

717


718

719

720 721

722

# 13.9 Figure 4: Relative risk of critical care admission in hospitalized adults with nosocomial and community-acquired COVID-19




Forest plot assessing the relative risk (RR) and 95% confidence interval (95% CI) of critical care admission in adults hospitalized with community-acquired and probable nosocomial COVID-19. The size of each box is proportional to the size of the individual hospital site (A-N), with the error bars representing the 95% Cls. The diamond represents the pooled average across studies, based on a random effects (RE) model. 1<sup>2</sup>: heterogeneity variance, calculated using restricted effects maximum likelihood (REML).

# 13.10 Figure 5: Funnel plot

723

725

726



Funnel plot with pseudo 95% confidence limits showing the distribution of relative risk of mortality across individual studies. Egger's test, p=0.51.